VJHemOnc is committed to improving our service to you

MDS 2020 | Combination therapies with azacitidine for MDS

VJHemOnc is committed to improving our service to you

Mikkael Sekeres

Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses azacitidine monotherapy versus a combination with lenalidomide or vorinostat to treat myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter